Information Provided By: 
Fly News Breaks for December 19, 2017
BVX
Dec 19, 2017 | 14:53 EDT
Craig-Hallum analyst Matt Hewitt wrote in a research note that while Rob Gershon's resignation as CEO of Bovie Medical on Monday and the subsequent appointment of Charlie Goodwin was a bit "unexpected," some investors had been asking for a change, so the news may be viewed as a positive. Hewitt maintained a Buy rating and $4.50 price target on Bovie Medical shares.
News For BVX From the Last 2 Days
There are no results for your query BVX
